3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
2
Recurrence
1
Hormone Receptor Positive Breast Carcinoma
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Endometrial Neoplasms
1
Carcinoma, Ductal, Breast
1
Advanced HER2+Breast Cancer
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
15
Paclitaxel
15
Carboplatin
13
Specimen Handling
6
Biopsy
6
durvalumab
5
Magnetic Resonance Spectroscopy
5
dostarlimab
4
Taxes
4
Surveys and Questionnaires
4
Observation
4
Letrozole
4
Everolimus
4
Cisplatin
4
olaparib
3
lenvatinib
3
ceralasertib
3
Doxorubicin
3
sacituzumab govitecan
2
pertuzumab
2
copanlisib
2
cabozantinib
2
atezolizumab
2
abemaciclib
2
Trastuzumab
2
Robotic Surgical Procedures
2
Radiotherapy
2
Radiation
2
Pemetrexed
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Endometrial Neoplasms
×
Alpelisib
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled